Exosomal Noncoding RNAs and Tumor Drug Resistance

Guo, Chengyao; Wang, Zhibin; Zhou, Quanbo; Song, Junmin; Zhang, Zhiyong; Li, Zhen; Wang, Guixian; Yuan, Weitang; Sun, Zhenqiang

doi:10.1158/0008-5472.can-20-0032

Cited by 30 publications

(22 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, EVs are appreciated as essential mediators of cell-to-cell communication. In the field of cancer biology, EVs have been found to play crucial roles in cancer metastasis [ 189 ] and drug resistance [ 190 , 191 , 192 , 193 , 194 , 195 ]. In oral cancer, EVs also mediate drug resistance by transferring their cargoes to recipient cells [ 196 , 197 , 198 , 199 , 200 , 201 , 202 ].…”

Section: Extracellular Vesicles: Evsmentioning

confidence: 99%

Impact of Non-Coding RNAs on Chemotherapeutic Resistance in Oral Cancer

et al. 2022

View full text Add to dashboard Cite

Drug resistance in oral cancer is one of the major problems in oral cancer therapy because therapeutic failure directly results in tumor recurrence and eventually in metastasis. Accumulating evidence has demonstrated the involvement of non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), in processes related to the development of drug resistance. A number of studies have shown that ncRNAs modulate gene expression at the transcriptional or translational level and regulate biological processes, such as epithelial-to-mesenchymal transition, apoptosis, DNA repair and drug efflux, which are tightly associated with drug resistance acquisition in many types of cancer. Interestingly, these ncRNAs are commonly detected in extracellular vesicles (EVs) and are known to be delivered into surrounding cells. This intercellular communication via EVs is currently considered to be important for acquired drug resistance. Here, we review the recent advances in the study of drug resistance in oral cancer by mainly focusing on the function of ncRNAs, since an increasing number of studies have suggested that ncRNAs could be therapeutic targets as well as biomarkers for cancer diagnosis.

show abstract

Section: Extracellular Vesicles: Evsmentioning

confidence: 99%

Impact of Non-Coding RNAs on Chemotherapeutic Resistance in Oral Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Another effective strategy for exosome-targeted therapy is to inhibit the uptake of exosomes with recipient cells. Heparan sulfate proteoglycans (HSPGs) are internalizing receptors of cancer-derived exosomes which could significantly attenuate exosomes uptake [129]. In addition, Reg3β, a lectin binding to the surface of exosomes, was released by normal pancreatic tissue surrounding tumors.…”

Section: As Therapeutic Targetmentioning

confidence: 99%

The Role of Exosomes and Their Applications in Cancer

Zhou

Zhang

Gong

et al. 2021

IJMS

View full text Add to dashboard Cite

Exosomes are very small extracellular vesicles secreted by multiple cell types and are extensively distributed in various biological fluids. Recent research indicated that exosomes can participate in regulating the tumor microenvironment and impacting tumor proliferation and progression. Due to the extensive enrollment in cancer development, exosomes have become a focus of the search for a new therapeutic method for cancer. Exosomes can be utilized for the therapeutic delivery of small molecules, proteins and RNAs to target cancer cells with a high efficiency. Exosome-carried proteins, lipids and nucleic acids are being tested as promising biomarkers for cancer diagnosis and prognosis, even as potential treatment targets for cancer. Moreover, different sources of exosomes exhibit multiple performances in cancer applications. In this review, we elaborate on the specific mechanism by which exosomes affect the communication between tumors and the microenvironment and state the therapeutic and diagnostic applications of exosomes in cancers.

show abstract

“…Even worse, treatment can promote metastasis and cancer lethality (D'Alterio et al, 2020 ; Pienta et al, 2020a , b ). There are many viewpoints/assumptions to explain the mechanisms of drug resistance: multiple drug resistance, cancer stem cells, cellular adaptation and collaboration, epigenetic regulation, cancer heterogenicity, persistent cancer cells, exosomal non-coding RNAs, acquired immune-resistance, and tumor micro-environments including tumor-stromal cross-talk (Heng et al, 2010 ; Holohan et al, 2013 ; Keating et al, 2013 ; Niero et al, 2014 ; Restifo et al, 2016 ; Cho and Kim, 2020 ; Guo et al, 2020 ; Shen et al, 2020 ; Swayden et al, 2020 ; Bhattacharya et al, 2021 ). Among them, new gene mutations and, in particular, selection of preexisting variants by drug treatment are the most popular mechanisms of cancer drug resistance (Khong and Restifo, 2002 ; Aktipis et al, 2011 ; Heng, 2015 , 2019 ).…”

Section: The Questionsmentioning

confidence: 99%